Cluster analysis of clinical data identifies fibromyalgia subgroups. by Docampo Martinez, Elisa et al.
Cluster Analysis of Clinical Data Identifies Fibromyalgia
Subgroups
Elisa Docampo1,2,3, Antonio Collado4,9*, Geo`rgia Escaramı´s1,2,3, Jordi Carbonell5,9, Javier Rivera6,9,
Javier Vidal7,9, Jose´ Alegre8,9, Raquel Rabionet1,2,3., Xavier Estivill1,2,3.
1Genomics and Disease Group, Centre for Genomic Regulation (CRG), Barcelona, Spain, 2Universitat Pompeu Fabra (UPF), Barcelona, Spain, 3Centro de Investigacio´n
Biome´dica en Red en Epidemiologı´a y Salud Pu´blica (CIBERESP), Barcelona, Spain, 4 Fibromyalgia Unit, Rheumatology Service, Hospital Clı´nic, Barcelona, Spain,
5 Fibromyalgia Unit, Rheumatology Service, Parc de Salut Mar; and Hospital del Mar Research Institute, Barcelona, Spain, 6 Rheumatology Unit, Instituto Provincial de
Rehabilitacio´n, Hospital Universitario Gregorio Maran˜o´n, Madrid, Spain, 7 Rheumatology Unit, Hospital General de Guadalajara, Guadalajara, Spain, 8Chronic Fatigue
Syndrome Unit, Hospital Vall d’Hebron, Barcelona, Spain, 9 Fibromyalgia and Chronic Fatigue Syndrome, Spanish Genetic and Clinical Data Bank Group, Foundation
Fibromyalgia and Fatigue, Barcelona, Spain
Abstract
Introduction: Fibromyalgia (FM) is mainly characterized by widespread pain and multiple accompanying symptoms, which
hinder FM assessment and management. In order to reduce FM heterogeneity we classified clinical data into simplified
dimensions that were used to define FM subgroups.
Material and Methods: 48 variables were evaluated in 1,446 Spanish FM cases fulfilling 1990 ACR FM criteria. A partitioning
analysis was performed to find groups of variables similar to each other. Similarities between variables were identified and
the variables were grouped into dimensions. This was performed in a subset of 559 patients, and cross-validated in the
remaining 887 patients. For each sample and dimension, a composite index was obtained based on the weights of the
variables included in the dimension. Finally, a clustering procedure was applied to the indexes, resulting in FM subgroups.
Results: Variables clustered into three independent dimensions: ‘‘symptomatology’’, ‘‘comorbidities’’ and ‘‘clinical scales’’.
Only the two first dimensions were considered for the construction of FM subgroups. Resulting scores classified FM samples
into three subgroups: low symptomatology and comorbidities (Cluster 1), high symptomatology and comorbidities (Cluster
2), and high symptomatology but low comorbidities (Cluster 3), showing differences in measures of disease severity.
Conclusions: We have identified three subgroups of FM samples in a large cohort of FM by clustering clinical data. Our
analysis stresses the importance of family and personal history of FM comorbidities. Also, the resulting patient clusters could
indicate different forms of the disease, relevant to future research, and might have an impact on clinical assessment.
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Introduction
Fibromyalgia (FM) is a disorder characterized by widespread
pain and accompanying symptoms such as fatigue, disturbed sleep
and variable degrees of anxiety and depression [1]. It is a very
heterogeneous disease, including different types of symptoms of
different systems. In fact, it has even been defined as an overlap of
syndromes and symptoms rather than as a discrete entity [2].
Diagnosis of fibromyalgia is based on clinical features. Despite
the development of new clinical diagnostic criteria [3,4], it is
difficult to define and assess the severity of FM, due to its
multidimensional nature and the lack of specific disease markers
[5]. In addition, the heterogeneity of FM hinders the character-
ization of the interactions among its clinical features, and their
relationship with treatment outcome. Thus, many investigators in
the field have suggested that there is a need for empirically derived
groups that could help to tailor more specific therapies to each
patient [6] and quantify health care usage [7].
One of the most characteristic methods for grouping symptoms
of a given disorder is cluster analysis. It consists of a multivariate
statistical technique that evaluates the degree of similarity among
heterogeneous variables in order to identify related groups of
variables based on these similarities [8]. Cluster analysis has been
widely used to identify patient-relevant clinical features to be used
in patient orientated management strategies, especially in the
oncology field. It has also been applied to other disorders in an
effort to understand the relationships among clinical features and
outcome variables. In fact, some studies have already attempted to
define FM subgroups by performing cluster analysis of FM
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symptoms. These studies differed on sample sizes, variables studied
and methods used. In most cases, cluster analysis was used to
categorize FM patients based on somatic or psychological
symptoms [9,10], quantitative sensory testing [11] or pressure-
pain thresholds and psychological factors [12]. A recent study tried
to discern clinically relevant subgroups across psychological and
biomedical domains [13], while another attempted to identify
clusters of clinical features meaningful to FM patients that
corresponded to their treatment priority goals in the context of
desired improvement [2]. Finally, a recent work [14] indicated the
existence of two latent dimensions underlying FM symptomatol-
ogy: FM core symptoms and distress. Most of these studies have
been performed in small cohorts taking into account few clinical
variables, and using clustering to group either variables or patients.
Only three studies were performed in large cohorts [7,10,15]. In
these studies, patients were assessed through web based methods
with the purpose to evaluate patients perception of symptoms
management [15] or to examine differences among FM subgroups
in healthcare utilization [7]. Despite the various attempts at
classification, there is yet no clear subgrouping of patients or
clinical variables that will help in the management of the disease.
In the present study, we want to analyze the co-occurrence in
the patients of the clinical variables collected in a large cohort of
FM cases, and identify groups of clinical features that would
enable to distinguish subgroups of FM patients. The main
objective is to describe possible subgroups of patients that may
be found in the clinical practice, which may help to understand the
disease. We will do this by building a set of dimensions of clinical
data, with the inclusion of personal and family comorbidities in
addition to physical and psychological symptoms, and then testing
its validity in the identification of FM subtypes. We have used a
large cohort of 1,446 FM cases, very well characterized at the
clinical level, through physician direct interview and physical
examination in specialized fibromyalgia units.
Materials and Methods
Samples
Data for 1,446 FM patients was obtained from the Fibromy-
algia and Chronic Fatigue Syndrome Spanish Genetic and
Clinical Data Bank (FFSGCDB) [16] (www.bancoadn.org). The
biological and clinical data were collected at the FM units of five
Spanish Hospitals. Patients fulfilling the 1990 ACR criteria [1]
were selected for inclusion in the study and subsequently evaluated
by a set of physicians trained in the evaluation of FM patients. An
initial set of 559 unrelated FM cases was considered for the
analysis; the same cluster analysis was performed in a second set of
887 cases. The analysis of the relationship between clustered
groups and severity of clinical core variables was performed in the
entire cohort of 1,446 patients.
Ethics
All patients were of Spanish Caucasian origin and had signed
informed consent before enrollment. The ethics committee at all
recruitment centers, Hospital del Mar (Barcelona) Hospital Clı´nic i
Provincial (Barcelona), Hospital de la Vall d’Hebro´n (Barcelona),
Hospital Gregorio Maran˜o´n (Madrid) and Hospital General de
Guadalajara (Guadalajara), approved the project.
Variables
Data collection followed a standard protocol of questionnaires
and physical examination that were recorded by principal
investigators of FFSGCDB. It included collection of demographic
variables (age, marital status, educational level, and occupational
status), family and personal history of diseases, FM clinical
features, fulfillment of CFS criteria, and treatments. Core
measures of FM symptoms and comorbidities were assessed by
different Spanish validated scales: pain and fatigue visual analogue
scale (VAS), number of tender points [17], Hospital Anxiety and
Depression Scale (HAD) [18,19], Pittsburg Sleep Quality Index
(PSQI) [20], Fibromyalgia Impact Questionnaire (FIQ) [21],
Fatigue Impact severity Scale (FIS) [22,23] and Quality of Life
survey (SF-36) [24,25].
After exclusion of treatment and socio-demographic variables,
48 variables were selected for the clustering analysis, based on
clinical experience, including symptoms defined in the literature
and somatic symptoms used in the new diagnostic criteria (List S1)
[3].
These variables can easily be recorded in routine diagnostic
procedures: 12 of them are related with personal and family
history of medical or psychopathological comorbidities; 4 variables
are related to disease evolution; 10 variables correspond to clinical
scales and the remaining 22 variables are somatic symptoms.
Cluster analysis with an admixture of continuous and dichot-
omous variables lead to a clustering of the variables upon their
nature. For this reason and taking into account that 75% of the
variables considered in the study were dichotomous, the non-
dichotomous variables were transformed into binary types
(0 =mild; 1 = severe), simplifying the distance analysis but taking
into account the severity of the variable. For symptoms
(dichotomous variables), the presence of the symptom was codified
as 1 and the absence as 0. For continuous variables, the median
was considered as a robust cut-off value, as the distribution of the
quantitative variables was asymmetrical (Figure S1). For scales,
values below the median were codified as 0 and values above the
median as 1, while for age of onset, as a younger age of onset (#38
years) is considered more severe, the codification was reversed.
Variables included in the cluster analysis, as well as their medians
(interquartile range), are summarized in List S1 and Table 1.
Statistical Analysis
Building variable’s dimensions. The underlying dimen-
sions of FM were evaluated using partitioning cluster analysis. This is a
method to partition data into meaningful subgroups when the
number of subgroups and other information about their compo-
sition may be unknown [26]. The basic procedure behind
partitioning cluster analysis is to construct subgroups with
homogeneous objects, which in our study are clinical variables,
based on a well-defined proximity measure. Given the non-
continuous nature of our variables, we used the Gower’s general
similarity measure [27]. We used a robust approach called position
around medoids (PAM), where group membership depends on
proximity to an actual observation (medoid) instead of proximity
to an average object (centroid). The number of clusters or
subgroups was determined using silhouette plots and Calinski’s
index. The names for each of the subgroups were determined post-
hoc in an attempt to characterize the nature of each FM
dimension.
The clustering was constructed in an initial sample of 559 FM
patients, and a replication of the analysis was performed in a
second sample of 887 patients (see Figure S2).
Construction of samples subgroups. The clustering tool to
define the underlying FM dimensions was used to further construct
patient synthetic indexes based on the clinical features composition
of each FM dimension. The values of the synthetic indexes were
calculated from linear functions (one per each dimension, see
Methods S1) that weight the dichotomous variables that constitute
the specific dimension. The weighting factor is based on the
Fibromyalgia Cluster Analysis
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Table 1. Summary of the three different dimensions that emerged after cluster analysis.
VARIABLE VALUES WEIGHT NEIGHBOUR
DIMENSION 1: Symptoms and their characteristics
Widespread pain 0 = No 1 = yes 0.417062 3
Muscle weakness 0 = No 1 = yes 0.403494 3
Post exercise fatigue 0 = No 1 = yes 0.401630 3
Morning stiffness 0 = No 1 = yes 0.386802 3
Muscular contractures 0 = No 1 = yes 0.370318 3
Concentration problems 0 = No 1 = yes 0.363702 3
Memory complaints 0 = No 1 = yes 0.343472 3
Onset 0 = Progressive 1 = Sudden 0.327471 3
Sleep Disturbances 0 = No 1 = yes 0.295485 3
Forgetfulness 0 = No 1 = yes 0.232666 3
Migratory joint pain 0 = No 1 = yes 0.232439 3
Headache 0 = No 1 = yes 0.196143 3
Pain subtle movements impairment 0 = No 1 = yes 0.192320 3
Intestinal dysfunction 0 = No 1 = yes 0.188124 3
Visual accommodation impairment 0 = No 1 = yes 0.134756 3
Trigger 0 = No 1 = yes 0.128889 3
Dizziness 0 = No 1 = yes 0.106305 3
Excessive Perspiration 0 = No 1 = yes 0.103443 3
Months of pain (96; p25:48; p75:156) 0#96 1$96 0.097555 3
Personal history of chronic pain 0 = No 1 = yes 0.081029 3
Palpitations 0 = No 1 = yes 0.079645 3
Age of onset (38; p25:30; p75:45) 0$38 1#38 0.039180 3
DIMENSION 2: Personal and family comorbidities
Posttraumatic stress disorder 0 = No 1 = yes 0.574638 3
Personality disorders 0 = No 1 = yes 0.573018 3
Family history of autoimmune disorders 0 = No 1 = yes 0.555378 3
Family history of chronic fatigue syndrome 0 = No 1 = yes 0.554531 3
Panic attacks 0 = No 1 = yes 0.491861 3
Family history of fibromyalgia 0 = No 1 = yes 0.466244 3
Blackouts 0 = No 1 = yes 0.456721 3
Facial oedema 0 = No 1 = yes 0.432674 3
Connective disorder 0 = FM 1 = FM+CFS 0.395716 3
Adjustment disorder 0 = No 1 = yes 0.363677 3
Previous Personal history psychopathology 0 = No 1 = yes 0.321596 3
Major depression 0 = No 1 = yes 0.295372 3
Family history of chronic pain 0 = No 1 = yes 0.188152 3
Impaired urination 0 = No 1 = yes 0.155414 3
Spine osteoarthritis 0 = No 1 = yes 0.116031 3
Life quality SF-36 physical subscale (27; p25:22; p75:32) 0$27 1#27 0.071334 3
Life quality SF36 mental subscale (35; p25:25; p75:48) 0$35 1#35 0.004091 1
DIMENSION 3: Scales
HAD depression subscale (10; p25:7; p75:14) 0#10 1$10 0.266515 2
Fibromyalgia Impact Questionnaire (FIQ) (74.66; p25:63.05; p75:84.25) 0#74.66 1$74.66 0.249480 1
Fatigue Impact Scale (FIS) (66; p25:56.50; p75:75.00) 0#66 1$66 0.241993 1
Pain level (VAS 1–10 cm) (7.5; p25:6.5; p75:8.5) 0#7.5 1$7.5 0.196313 2
Pittsburgh Sleep Quality Index (PSQI) (14; p25:11; p75:17) 0#14 1$14 0.194950 1
Fatigue level (VAS 1–10 cm) (8; p25:6.4; p75:9) 0#8 1$8 0.191182 1
HAD anxiety subscale (12; p25:8; p75:15) 0#12 1$12 0.105136 1
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silhouette value of the specific variable in the cluster to which it is
assigned. The silhouette values take meaningful values from 1 (well
assigned) to 21 (closer to variables assigned to neighboring
clusters), where 0 indicates no clear assignment. The resulting
values of the synthetic indexes result into continuous measures for
each FM dimension.
The synthetic indexed values calculated per each sample and
dimension where then used to find patient subgroups. Given now
the continuous nature of the measures we used the K-means
clustering procedure to group patients with similar FM profiles
into three meaningful subgroups.
ANOVA analyses were used to compare the behavior of the 11
measured clinical scales in the defined FM subgroups, and are
shown in table 2.
All analyses were performed in the R environment (R software
version 2.14.1), using the cluster and fpc packages.
Results
1,446 FM samples of Caucasian origin were included in the
study. Of these, 97.2% were women with a mean age of 49610
years; more than two thirds (70.5%) were married; more than a
third (37.5%) had a high school degree and an additional 19,3%
had gone to university; and 80% of the patients had a paid
employment.
In the first dataset of 559 unrelated FM cases, the selected 48
clinical variables clustered into three independent dimensions.
Based on their composition, the dimensions were labeled as: FM
symptoms and their characteristics (Dimension 1: ‘‘symptomatol-
ogy’’), familial and personal comorbidities (Dimension 2: ‘‘comor-
bidities’’) and FM core clinical scales (Dimension 3: ‘‘scales’’)
(Figure 1, Table 1). The composition of the resulting dimensions
was homogeneous: only four variables (trembling, personal history
of chronic pain and SF-36 mental and physical subscales) clustered
in apparently unrelated dimensions. Since their weights within the
respective dimension were among the lowest, their effect on the
subsequent FM classification was reduced.
The same analysis was performed on these variables in a second
cohort of 887 patients, obtaining the same dimensions (Figure S2).
Given this confirmation, a global analysis was performed using the
whole cohort to obtain a global weight for each variable in order
to perform patient classification.
In order to maximize the number of samples classified into
subgroups, it was decided to use only the two dimensions
considered more reliable (‘‘symptomatology’’ and ‘‘comorbidi-
ties’’). On one hand, these dimensions included more variables
with higher weights making them more reliable. In addition, we
considered the possibility that the clustering of all clinical scales in
a dimension could be due to the nature of the variables and not
necessarily to their behavior in patients’ classification. This also
allowed the subsequent use of core clinical scales for the
assessment of the resulting subgroups and their disease severity.
Using the scales in this way allowed us to maximize the
information from the scales. For each FM sample, a composite
Table 2. Means 6 standard error of the mean (SEM) of different pain, psychiatric and quality of life scores in each of the
fibromyalgia clinical subgroups.
VARIABLE Cluster 1 Cluster 2 Cluster 3 P-value
FM LowLow (n=283) FM HighHigh (n =357) FM HighLow (n=758)
Fibromyalgia Impact Questionnaire (FIQ) 59.4661.16 77.6960.72 73.1660.52 p,0.001
Fatigue Impact Scale (FIS) 65.1060.72 69.0260.57 53.3760.6 p,0.001
Pain level (VAS 1–10 cm) 6.3060.12 7.8860.08 7.4360.06 p,0.001
Fatigue level (VAS 1–10 cm) 6.3360.14 7.9860.09 7.4360.07 p,0.001
Number of Tender Points 13.5460.21 15.5460.14 15.2460.1 p,0.001
Life quality SF-36 physical subscale 30.760.62 26.7160.36 26.8660.28 p,0.001
Life quality (SF36) mental 42.1260.86 31.7360.67 36.0860.49 p,0.001
HAD anxiety subscale 9.5460.27 13.0360.23 12.1260.16 p,0.001
HAD depression subscale 7.4860.27 11.4860.24 10.3960.16 p,0.001
Pittsburgh Sleep Quality Index (PSQI) 11.2860.26 15.3560.18 14.2760.14 p,0.001
Years of disease evolution 11.1460.57 13.6060.57 11.6360.67 0.07
P-value of multinomial analysis.
doi:10.1371/journal.pone.0074873.t002
Figure 1. Clustering of variables into three dimensions. Crosses,
triangles and circles represent variables assigned to each of the
dimensions. X and Y axis represent the two first principal components
of a PCA analysis used to reduce the dimensionality of the data in order
to be able to illustrate the clustering results.
doi:10.1371/journal.pone.0074873.g001
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index (score) was calculated for these two selected dimensions. The
resulting scores were used to classify 1,398 out of the 1,446 FM
samples. Cases were classified into three subgroups: low
symptomatology and low levels of familial and personal comor-
bidities (Cluster 1; 283 cases (20.2%)), high symptomatology and
high comorbidities (Cluster 2; 357 cases (25.6%)), and high
symptomatology but low comorbidities (Cluster 3; 758 cases
(54.2%)) (Figure 2).
The resulting FM subgroups presented no differences in terms
of gender, age, marital status, and employment. However, patients
having higher levels of education (high school degree and above)
were more represented in cluster 1 than in the other clusters
(p = 0.015 chi-square test).
This symptom-based classification correlated with the data from
the scales measuring pain, fatigue, psychiatric symptoms, and their
impact in life, as individuals belonging to the low symptomatology
and low comorbidities group had lower medians for the scales
(Table 2).
When the relationship between FM subgroups and core
measures of severity was analyzed, Cluster 1 was markedly
different from Cluster 2 and Cluster 3 in all scales, identifying the
less affected group. Cluster 2 was more affected than Cluster 3, but
differences were not as significant as with Cluster 1 in comparison
with the other two groups (Table 2).
The FM subgroup with high pain and comorbidities was also
the one with the highest level of fatigue (fatigue VAS higher than
pain VAS) and, in fact, 20% of the patients in this cluster fulfilled
also chronic fatigue syndrome (CFS) criteria [28] (FM+CFS),
whereas in the other two clusters only 8 (Cluster 1) and 11%
(Cluster 3) of the patients were fulfilling CFS criteria. Although
pain VAS was the highest in this cluster, the number of tender
points was not significantly different between both high pain
clusters.
Discussion
In this study we present a clustering of clinical data and
subsequent FM subgrouping in a large cohort of FM patients.
These findings were replicated in a second larger cohort, thus
conferring a stronger robustness to our results. To our knowledge,
this is the first study to perform a two-step clustering process to
define variables’ dimensions and subsequently identify FM
subgroups. The inclusion of personal and family history of
comorbidities and the collection of data through direct physician
examination constitute also novel contributions to FM cluster
analysis.
Based on our data, the variables were grouped into three
dimensions: FM symptoms and their characteristics (Dimension 1),
familial and personal comorbidities (Dimension 2) and scales
(Dimension 3). This clustering of variables into different dimen-
sions within FM syndrome is in agreement with previous works
[15]. The resulting variables dimensions are not completely
unexpected, as some of the observed clustering can be attributed to
the variables referring to the same symptom or organ (e.g.
muscular symptoms in dimension 1).
A novelty of our findings is that pain symptoms were grouped
with the cognitive symptoms into the first dimension. Since
symptoms within a cluster may share a common identifiable
etiology [8], this clustering could be highlighting the central
nervous system implication in the physiopathology of FM [29].
Nevertheless, previous studies did not show the clustering of FM
core symptoms and cognitive symptoms. In some cases, cognitive
symptoms were not considered [2,12,13], or physical and
psychological symptoms were considered separately [7], but in
the study by Rutledge et al. (2009) [15], where both were
considered, pain and cognitive symptoms did not cluster together.
A possible explanation for these contradictory results is that in this
study the evaluation was focused on the patients’ management of
the symptoms and which ones the patients wanted to be improved,
and not only the presence of the symptom. Another possible
explanation could be that their data were collected in a different
way, through online questionnaires instead of through a physi-
cian’s interview. The clustering of family history and personal
comorbidities into a second dimension is also consistent with the
fact that a family history of FM is linked with a more severe disease
with more comorbidities [30]. Although this is an interesting
finding of our study, it also constitutes a limitation, in that we
cannot discriminate the relative weight of personal and family
history of comorbidities, since they cluster together. However,
personal history of chronic pain before extensive pain clustered in
the first dimension, although presenting a low weight in the
dimension. The fact that the history of chronic pain did not cluster
with other comorbidities could be indicating that it may be
considered as a supporting FM core symptom. In fact, it is difficult
to identify the real onset of fibromyalgia, and whether the previous
regional chronic pain belongs to the disease itself.
Finally, the cluster of scale-type variables in the third dimension
could be due to the nature of the variables themselves rather than
their clinical value. In fact, in order to cluster the scales with the
dichotomous variables, they were transformed into binomial
variables, which could have limited their clinical value. However
the dichotomization of these variables improved the results by
providing different meaningful clusters based on the symptoms
and comorbidities variables, which were all them dichotomous. In
any case, this last dimension was the one with the fewer variables
and the lowest weights, making the dimension less reliable than the
other two. Since the main purpose of clinical scales is to measure
Figure 2. Subgrouping of fibromyalgia (FM) samples based on
their ‘‘familial and personal comorbidities’’ (Y axis) and ‘‘FM
symptoms and their characteristics’’ (X-axis) scores. Circles
represent FM patients and are colored by cluster. Black circles for
Cluster 1 (Low levels of symptoms and their characteristics and low
levels of comorbidities), green circles for Cluster 2 (High levels of
symptoms and high levels of comorbidities), and red circles for Cluster 3
(High levels of symptoms and low levels of comorbidities).
doi:10.1371/journal.pone.0074873.g002
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severity (constituting also a screening method), they were finally
used to evaluate differences among the resulting FM subgroups.
Once the clustering of the samples was performed based on
their scores in the first and second dimension only, the samples
formed three groups: low symptomatology and low familiar and
personal comorbidities (Cluster 1), high symptomatology and high
familiar and personal comorbidities (Cluster 2) and high symp-
tomatology but low familial and personal comorbidities (Cluster 3).
Nevertheless, as shown in Figure 2, these three groups were not
clearly separated, and the cut-offs used were empirically derived
from our data (by k-means clustering method), and would be
dependent of the specific cohort analysed.
We did not observe differences in age or gender among the
subsets. It has to be taken into account that due to the reduced
number of males included in the study (49 individuals), we were
underpowered to exclude a possible difference in the distribution
of males and females among subgroups. In agreement with
previous works [7,9], we found no age differences between the
subgroups, neither in age at the time of recruitment nor in the age
of onset. We did observe that patients included in Cluster 1
showed markedly lower values for all scales (Table 2). This could
be pointing to a milder form of FM, or to a less evolved disease.
However, we evaluated time of evolution of the disease and did
not observe statistical differences between the three clusters,
although patients belonging to Cluster 2 seemed to have a longer
disease evolution (Table 2). This would indicate that the
differences among the clusters are not related to disease staging,
and could point to the identification of different clinical subsets. A
prospective study would be useful to elucidate if the less affected
Cluster 1 could have a better prognosis.
FM patients belonging to Cluster 2 (high symptomatology and
high comorbidities) were also the ones with the highest levels of
pain. This should not be unexpected, as most comorbidities are
psychiatric, and individuals with pain have been shown to be more
prone to depression because of pain’s adverse effects on mood and
physical function [8]. Furthermore, previous cluster analyses
showed that depression, fatigue and pain were all significantly
correlated to each other (and to total health status) in persons with
breast cancer [31], and that the number of depressive symptoms
was a factor associated with the development of chronic
widespread pain [32]. Comorbid medical conditions could also
be responsible for a greater severity of FM symptoms in Cluster 2.
However, differences between Clusters 2 and 3 in FM core
measures observed in our study, although statistically significant,
were limited. This could be indicative of a limited influence of
personal or family history of chronic pain and psychopathology in
disease severity, showing that the presence of high number of
symptoms is the main marker of disease severity.
The FM subgroups that arise from our study are similar to the
ones described in previous works [7,10,12]. In the analysis
presented by Giesecke et al. (2003) [12], they also identified three
subsets of patients, mainly based in pain and psychopathology: 1)
moderate mood ratings, moderate levels of catastrophizing and
perceived control over pain and low levels of tenderness; 2)
elevated mood ratings, high levels of catastrophizing and low level
of perceived control over pain and high levels of tenderness; and 3)
normal mood ratings, low levels of catastrophizing and high level
of perceived control over pain and extreme tenderness. Appar-
ently, their groups show similarities with our findings, despite
analyzing different variables. Nevertheless, our results and the
results presented in Giesecke et al. (2003) [12] results are not
directly comparable, as they used measurements of experimental
pain and some variables not included in our study. Also,
comparison of our results with those presented in the study by
Rehm et al. (2010) [10] is difficult, as they use specific pain
characteristics that were not evaluated in our work. Finally, in the
study by Wilson et al. (2009) [7], they conducted a cluster analysis
on the physical and psychological symptoms to identify subgroups.
Subgroups I and IV of the classification in Wilson et al. (2009) [7]
seem to correspond to the groups II and I of our classification,
respectively. It would be interesting to test the degree of similarity
between the resulting groups of each study. In their study, as in the
present study, the group of patients with lower levels of
symptomatology had higher education levels. Differences in the
study design (use of web-based surveys, and exclusion of personal
and family comorbidities) could explain the resulting four groups
instead of three. However, both Wilson et al. (2009) and the
present study highlight the importance of symptoms in FM patient
classification. This is, indeed, in agreement with the new
diagnostic and classification criteria of fibromyalgia [3]. One of
the weaknesses of comparing classification methods of FM patients
is that a different set of variables is considered in each of the
studies, and each combination of questionnaires is likely to yield its
own subgroups. Nevertheless, comparison of classifications of
different studies cannot be properly performed without actually
applying all the analysis to the same set of patients and directly
comparing the composition of each of the resulting subgroups. In
fact, it would be of interest to find a consensus regarding criteria
for subgrouping of fibromyalgia patients. Performing the various
types of classification in the same set of patients could help in
identifying the most relevant criteria. These subgroups could then
be reproduced in different patient populations and used for
response analysis in future trials.
In summary, we have built latent dimensions based on routinely
collected clinical data, which have allowed us to distinguish three
subsets of FM patients that show differences in severity of disease.
Our results indicate that the evaluation of personal and family
history of FM comorbidities can add important information to FM
classification based on somatic symptoms. It is possible that the
subgroups identified may show different prognosis or response to
intervention, but this has not been analyzed, and further studies in
this area would be of interest. Furthermore, the definition of
clinically homogeneous FM subgroups constitutes a key step for
research purposes leading to a better understanding of the
biological basis of FM.
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